125 related articles for article (PubMed ID: 31474027)
1. Role of a 19S Proteasome Subunit- PSMD10
Sahu I; Nanaware P; Mane M; Mulla SW; Roy S; Venkatraman P
Int J Stem Cells; 2019 Nov; 12(3):463-473. PubMed ID: 31474027
[TBL] [Abstract][Full Text] [Related]
2. A druggable pocket on PSMD10
M G MS; Chikhale R; Nanaware PP; Dalvi S; Venkatraman P
Eur J Pharmacol; 2022 Jan; 915():174718. PubMed ID: 34953804
[TBL] [Abstract][Full Text] [Related]
3. Novel Nexus with NFκB, β-catenin, and RB1 empowers PSMD10/Gankyrin to counteract TNF-α induced apoptosis establishing its oncogenic role.
Mulla SW; Venkatraman P
Int J Biochem Cell Biol; 2022 May; 146():106209. PubMed ID: 35378311
[TBL] [Abstract][Full Text] [Related]
4. The Oncoprotein Gankyrin/PSMD10 as a Target of Cancer Therapy.
Fujita J; Sakurai T
Adv Exp Med Biol; 2019; 1164():63-71. PubMed ID: 31576540
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
Kim TD; Oh S; Lightfoot SA; Shin S; Wren JD; Janknecht R
Int J Clin Exp Med; 2016; 9(6):10123-10134. PubMed ID: 28883898
[TBL] [Abstract][Full Text] [Related]
6. PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression.
Luo T; Fu J; Xu A; Su B; Ren Y; Li N; Zhu J; Zhao X; Dai R; Cao J; Wang B; Qin W; Jiang J; Li J; Wu M; Feng G; Chen Y; Wang H
Autophagy; 2016 Aug; 12(8):1355-71. PubMed ID: 25905985
[TBL] [Abstract][Full Text] [Related]
7. Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
Taheri T; Jamialahmadi K; Khadijeh F
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3413-3418. PubMed ID: 29286612
[TBL] [Abstract][Full Text] [Related]
8. Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer.
Li J; Guo Y
Curr Chem Biol; 2010; 4(1):13-19. PubMed ID: 32775187
[TBL] [Abstract][Full Text] [Related]
9. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.
Sun W; Ding J; Wu K; Ning BF; Wen W; Sun HY; Han T; Huang L; Dong LW; Yang W; Deng X; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2011 Oct; 54(4):1259-72. PubMed ID: 21735473
[TBL] [Abstract][Full Text] [Related]
10. Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.
Nanaware PP; Ramteke MP; Somavarapu AK; Venkatraman P
Proteins; 2014 Jul; 82(7):1283-300. PubMed ID: 24338975
[TBL] [Abstract][Full Text] [Related]
11. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.
Umemura A; Itoh Y; Itoh K; Yamaguchi K; Nakajima T; Higashitsuji H; Onoue H; Fukumoto M; Okanoue T; Fujita J
Hepatology; 2008 Feb; 47(2):493-502. PubMed ID: 18161051
[TBL] [Abstract][Full Text] [Related]
12. Gankyrin as a potential target for tumor therapy: evidence and perspectives.
Li H; Zhang J; Zhen C; Yang B; Feng L
Am J Transl Res; 2018; 10(7):1949-1960. PubMed ID: 30093934
[TBL] [Abstract][Full Text] [Related]
13. Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer.
Bai Z; Tai Y; Li W; Zhen C; Gu W; Jian Z; Wang Q; Lin JE; Zhao Q; Gong W; Liang B; Wang C; Zhou T
Cancer Res; 2013 Jul; 73(14):4548-58. PubMed ID: 23576566
[TBL] [Abstract][Full Text] [Related]
14. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
[TBL] [Abstract][Full Text] [Related]
15. Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome.
Nakamura Y; Nakano K; Umehara T; Kimura M; Hayashizaki Y; Tanaka A; Horikoshi M; Padmanabhan B; Yokoyama S
Structure; 2007 Feb; 15(2):179-89. PubMed ID: 17292836
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1.
Liu Y; Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Koike K; Hirota K; Fukumoto M; Fujita J
Biochem Biophys Res Commun; 2013 Mar; 432(1):22-7. PubMed ID: 23376718
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic analysis reveals the underlying pro-malignant functions of Gankyrin for colorectal cancer via affecting tumor necrosis factor pathway.
Xu B; Li S; Lv W; Wang Y; Li X; Zhang L; Lin J
Int J Biol Macromol; 2018 Oct; 117():1011-1016. PubMed ID: 29883699
[TBL] [Abstract][Full Text] [Related]
18. Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2.
Nitta RT; Smith CL; Kennedy BK
PLoS One; 2007 Sep; 2(9):e963. PubMed ID: 17896003
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer.
Riahi MM; Sistani NS; Zamani P; Abnous K; Jamialahmadi K
Neoplasma; 2017; 64(5):732-737. PubMed ID: 28592125
[TBL] [Abstract][Full Text] [Related]
20. Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI‑8226 multiple myeloma cells.
Du S; Qin W; Leng H; Chen Z; Zhang T
Oncol Rep; 2017 Aug; 38(2):809-818. PubMed ID: 28677774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
